Table 2.
Active ingredients disproportionately reported (IC025 >0) with tubulointerstitial nephritis, ranked by number of reports (only the 15 most reported drugs are displayed, see Supplementary Table S1 for a more comprehensive listing)
| Active ingredient | Number of reports (%) | ROR (95% CI) |
|---|---|---|
| Omeprazole | 4328 (27.6) | 84.5 (81.6–87.6) |
| Lansoprazole | 3571 (22.8) | 134.1 (129.1–139.3) |
| Esomeprazole | 3532 (22.5) | 79.6 (76.7–82.7) |
| Pantoprazole | 3185 (20.3) | 100 (96.2–104.1) |
| Dexlansoprazole | 2067 (13.2) | 209.9 (200–220.3) |
| Rabeprazole | 1142 (7.3) | 127.3 (119.6–135.4) |
| Ciprofloxacin | 529 (3.4) | 7.9 (7.3–8.7) |
| Ibuprofen | 497 (3.2) | 5.3 (4.9–5.8) |
| Vancomycin | 430 (2.7) | 10.8 (9.8–11.9) |
| Piperacillin/tazobactam | 399 (2.5) | 11.8 (10.7–13.1) |
| Mesalazine | 387 (2.5) | 35 (31.6–38.8) |
| Esomeprazole/naproxen | 309 (2) | 64.4 (57.5–72.2) |
| Diclofenac | 299 (1.9) | 3.5 (3.2–4) |
| Nivolumab | 293 (1.9) | 9.7 (8.6–10.9) |
| Sulfamethoxazole/trimethoprim | 292 (1.9) | 4.2 (3.7–4.7) |
ROR, reporting odds ratio.